

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 August 2024 (29.08.2024)



(10) International Publication Number
WO 2024/178255 A1

(51) International Patent Classification:

A61K 9/16 (2006.01) A61P 35/00 (2006.01)
A61K 31/403 (2006.01)

(21) International Application Number:

PCT/US2024/016952

(22) International Filing Date:

22 February 2024 (22.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/486,611	23 February 2023 (23.02.2023)	US
63/486,613	23 February 2023 (23.02.2023)	US
63/611,027	15 December 2023 (15.12.2023)	US

(71) Applicant: **VOLAISTRA THERAPEUTICS, INC.**
[US/US]; 1361 Amsterdam Avenue, Suite 520, New York,
New York 10027 (US).

(72) Inventor; and

(71) Applicant: **MAO, Jianmin**; c/o Volastra Therapeutics,
Inc., 1361 Amsterdam Avenue, Suite 520, New York, New
York 10027 (US).

(72) Inventors: **COGAN, Derek A.**; c/o Volastra Therapeutics,
Inc., 1361 Amsterdam Avenue, Suite 520, New York, New
York 10027 (US). **SU, Michael**; c/o Volastra Therapeutics,
Inc., 1361 Amsterdam Avenue, Suite 520, New York, New
York 10027 (US). **DRUTMAN, Scott**; c/o Volastra Ther-
apeutics, Inc., 1361 Amsterdam Avenue, Suite 520, New
York, New York 10027 (US).

(74) Agent: **DO, Keunbong et al.**; Morrison & Foerster LLP,
425 Market Street, San Francisco, California 94105 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

(54) Title: SOLID FORMULATIONS AND POLYMORPHIC FORMS OF INDOLINE INHIBITORS OF KIF18A




FIG. 2

(57) Abstract: The present disclosure relates to inhibitors of KIF18A, formulations thereof, polymorphic forms thereof, and methods of using said formulations and polymorphic forms thereof. More specifically, the present disclosure relates to solid formulations and polymorphic forms of a series of indoline inhibitors of KIF18A, methods of preparing such formulations and polymorphic forms, and methods of their use for treating disease mediated by KIF18A, such as cancer.

[Continued on next page]

WO 2024/178255 A1

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*